WAKO NEFA LINEARITY SET
K030065 · Wako Chemicals USA, Inc. · JJX · Feb 11, 2003 · Clinical Chemistry
Device Facts
| Record ID | K030065 |
| Device Name | WAKO NEFA LINEARITY SET |
| Applicant | Wako Chemicals USA, Inc. |
| Product Code | JJX · Clinical Chemistry |
| Decision Date | Feb 11, 2003 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 862.1660 |
| Device Class | Class 1 |
Intended Use
A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test sytem to estimate test precision and to detect systematic analytivcal deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed or unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls.
Device Story
Wako NEFA Linearity Set functions as quality control material for clinical chemistry testing. Device used in laboratory settings by technicians to monitor test system performance; specifically, to estimate precision and identify systematic analytical deviations resulting from reagent or instrument variability. Product serves as a reference standard to ensure accuracy and reliability of clinical chemistry assays. No automated processing or software components involved.
Clinical Evidence
No clinical data provided; bench testing only.
Technological Characteristics
Quality control material for clinical chemistry; liquid or lyophilized form; intended for use with analytical instruments to verify linearity and precision. No software, energy source, or complex mechanical components.
Indications for Use
Indicated for use as a quality control material in clinical chemistry test systems to estimate test precision and detect systematic analytical deviations caused by reagent or instrument variation; applicable for proficiency testing in interlaboratory surveys.
Regulatory Classification
Identification
A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls.
Related Devices
- K973072 — WAKO NEFA LINEARITY SET · Wako Chemicals USA, Inc. · Sep 12, 1997
- K040918 — WAKO LIPID CONTROL, LEVEL 1 AND LEVEL 2 · Wako Chemicals USA, Inc. · May 17, 2004
- K070741 — CLINIQA LIQUID QC UNASSAYED AND ASSAYED GENERAL CHEMISTRY CONTROL LEVELS 1, 2, & 3 · Cliniqa Corporation · May 4, 2007
- K110880 — VALIDATE (R) GC3 CALIBRATION VERIFICATION / LINEARITY TEST KIT · Maine Standards Company, LLC · Jul 5, 2011
- K060850 — NOD CHEMISTRY CONTROL · Bioresource Technology, Inc. · May 30, 2006
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES * USA" arranged around the top half of the circle. Inside the circle is a stylized image of an eagle with three curved lines representing its wings.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
FEB 1 1 2003
Ms. Tonya Mallory Executive Manager Wako Diagnostics 1600 Bellwood Road Richmond, VA 23237
Re: k030065 Trade/Device Name: Wako NEFA Linearity Set Regulation Number: 21 CFR 862.1660 Regulation Name: Ouality control material (assayed and unassayed) Regulatory Class: Class I Product Code: JJX Dated: January 6, 2003 Received: January 7, 2003
Dear Ms. Mallory:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820).
{1}------------------------------------------------
Page 2 –
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely vours.
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
## Indications for Use:
A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test sytem to estimate test precision and to detect systematic analytivcal deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed or unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls.
Proprietary Name: Wako NEFA Linearity Set
Established Registration Number: 1627434
Premarket Notification 510 (k) Number:
## (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use
(Per 21 CFR 801.109)
OR
Over-The-Counter Use (Optional Format 1-2-96)
Han Cooper
(Div
Div. Laboratory Devices
510(k) K030065